CD274 and cancer: Interestingly, a meta-analysis including 19 randomized clinical trials and 11,379 patients, showed that PD-1 inhibition leads to a higher OS and progression free survival (PFS) compared to PD-L1 inhibition (as single agent or in combination), in different types of cancers.